Comparative Pharmacology
Head-to-head clinical analysis: DETROL versus SANCTURA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DETROL versus SANCTURA.
DETROL vs SANCTURA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive muscarinic receptor antagonist, primarily targeting M3 receptors in the bladder, reducing detrusor muscle contractions and increasing bladder capacity.
Trospium chloride is an antimuscarinic agent that competitively inhibits acetylcholine at muscarinic receptors, thereby reducing detrusor muscle contractions and increasing bladder capacity.
2 mg orally twice daily; may increase to 4 mg daily in divided doses based on response.
20 mg orally twice daily, with or without food. Maximum dose 20 mg twice daily.
None Documented
None Documented
Terminal half-life 6.9 hours (range 4-10 hours) for tolterodine; 7.7 hours (range 5-13 hours) for active 5-hydroxymethyl metabolite; prolonged in hepatic impairment (up to 3-fold).
Terminal elimination half-life is approximately 12–20 hours in healthy adults, allowing twice-daily dosing.
Renal: 77% (as metabolites, <1% unchanged); Fecal: 17%; Biliary: minor.
Primarily renal (approximately 60% as unchanged drug and metabolites); biliary/fecal elimination accounts for ~30%.
Category C
Category C
Anticholinergic
Anticholinergic